Will Pfizer rebid for AstraZeneca? Keep an eye on U.S. midterm election for clues

Will Pfizer ($PFE) come back at AstraZeneca ($AZN)? That's been the question of the summer, especially since the U.S. Treasury Department rolled out new rules for tax-inversion deals. Now, sources are telling the Financial Times and CNBC that the collapse of AbbVie's ($ABBV) buyout of Ireland-based Shire ($SHPG) make another Pfizer bid unlikely. Unless the midterm elections go against President Obama, that is. Report | Report

Suggested Articles

Pfizer will exit its Perth, Australia sterile injectables manufacturing site by 2024 as part of a global production reorganization effort.

Agios has withdrawn a European application for Tibsovo in AML after the same phase 1 data that earned it an FDA nod failed to impress the EMA.

Sanofi is reportedly considering a sale of some of its anti-inflammation drugs that could snare $234 million as the company pivots toward Dupixent.